TG Therapeutics to Participate in the Evercore HealthCONx Conference
2024年11月29日 - 10:00PM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael
S. Weiss, the Company’s Chairman and Chief Executive Officer, will
participate in the 7th Annual Evercore HealthCONx Conference, being
held at the Loews Coral Gables Hotel, in Florida on December 3-5,
2024. The fireside chat is scheduled to take place on Tuesday,
December 3, at 10:00 AM ET.
A live webcast of the fireside chat will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICSTG Therapeutics is a fully
integrated, commercial stage, biopharmaceutical company focused on
the acquisition, development and commercialization of novel
treatments for B-cell diseases. In addition to a research pipeline
including several investigational medicines, TG has received U.S.
Food and Drug Administration (FDA) approval for BRIUMVI®
(ublituximab-xiiy), for the treatment of adult patients with
relapsing forms of multiple sclerosis (RMS), to include clinically
isolated syndrome, relapsing-remitting disease, and active
secondary progressive disease, as well as approval by the European
Commission (EC) and the Medicines and Healthcare Products
Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with
RMS who have active disease defined by clinical or imaging features
in Europe and the United Kingdom, respectively. For more
information, visit www.tgtherapeutics.com, and follow us on X
(formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor
RelationsEmail: ir@tgtxinc.comTelephone: 1.877.575.TGTX
(8489), Option 4
Media
Relations:Email: media@tgtxinc.comTelephone:
1.877.575.TGTX (8489), Option 6
TG Therapeutics (NASDAQ:TGTX)
過去 株価チャート
から 1 2025 まで 2 2025
TG Therapeutics (NASDAQ:TGTX)
過去 株価チャート
から 2 2024 まで 2 2025